Value-Based Pricing: Panacea, Building Block, or Pipe Dream?
Wednesday, March 21, 2018
4:30 p.m.–6 p.m. (doors open at 4 p.m.)
72 East Concord Street
This presentation will discuss value assessment—including the use of cost-effectiveness and budgetary impact analyses in decision-making—and will contrast approaches taken in other high-income countries with those in the United States. Daniel Ollendorf will touch on what is included in the umbrella term “value-based pricing,” and will discuss under what circumstances various approaches to negotiation, such as outcomes-based contracting, amortized payments, and negotiated discounts, may or may not be value based.
Prior to joining ICER, he was executive director, health economics and outcomes research, for IMS Health, where he was responsible for the operations of a $20 million franchise as well as the successful integration of a US consulting practice. Ollendorf also has served as vice president of applied research at PharMetrics (now a unit of IMS), where he managed the scientific team conducting a variety of research initiatives using integrated claims data; and as a senior consultant at Policy Analysis Inc. (PAI), where he designed and conducted health-economic, quality-of-life, and retrospective database analyses in a variety of therapeutic areas.
Ollendorf has authored more than 50 peer-reviewed articles in major journals, and was on the editorial board of the Journal of Managed Care Pharmacy from 2009 to 2012. He currently serves on the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), the ISPOR HTA Council Working Group, and the Policy Forum of Health Technology Assessment International (HTAi). He holds a PhD in clinical epidemiology from the University of Amsterdam, an MPH from Boston University, and a BA from the University of Rochester.